Adial Pharmaceuticals, Inc.

NasdaqCM:ADIL Stok Raporu

Piyasa değeri: US$6.5m

Adial Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 4/4

Adial Pharmaceuticals' CEO is Cary Claiborne, appointed in Aug 2022, has a tenure of 2.25 years. total yearly compensation is $801.62K, comprised of 58.1% salary and 41.9% bonuses, including company stock and options. directly owns 0.95% of the company’s shares, worth $61.41K. The average tenure of the management team and the board of directors is 3.8 years and 7.3 years respectively.

Anahtar bilgiler

Cary Claiborne

İcra Kurulu Başkanı

US$801.6k

Toplam tazminat

CEO maaş yüzdesi58.1%
CEO görev süresi2.3yrs
CEO sahipliği0.9%
Yönetim ortalama görev süresi3.8yrs
Yönetim Kurulu ortalama görev süresi7.3yrs

Son yönetim güncellemeleri

Recent updates

Adial Clinical Trial: A Fluff Or A Win?

Aug 22

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Aug 16

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Jun 21

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Jan 11

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Nov 25

CEO Tazminat Analizi

Cary Claiborne'un ücretlendirmesi Adial Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$12m

Mar 31 2024n/an/a

-US$11m

Dec 31 2023US$802kUS$466k

-US$7m

Sep 30 2023n/an/a

-US$8m

Jun 30 2023n/an/a

-US$9m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$1mUS$357k

-US$11m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$688kUS$15k

-US$19m

Tazminat ve Piyasa: Cary's total compensation ($USD801.62K) is about average for companies of similar size in the US market ($USD655.65K).

Tazminat ve Kazançlar: Cary's compensation has been consistent with company performance over the past year.


CEO

Cary Claiborne (63 yo)

2.3yrs

Görev süresi

US$801,621

Tazminat

Mr. Cary John Claiborne, MBA, is the Owner and Chief Executive Officer of Prosperity Capital Management LLC. He serves as an Independent Director at LadRx Corporation (formerly known as CytRx Corporation)...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Cary Claiborne
CEO, President & Director2.3yrsUS$801.62k0.95%
$ 61.4k
Joseph A. Truluck
CFO, Treasurer & Secretary7.4yrsUS$389.03k0.17%
$ 10.7k
John Martin
Chief Legal Officer3.8yrsVeri yokVeri yok
Andrew Taubman
Vice President of Corporate Developmentno dataVeri yokVeri yok
Catherine Fratila
Controller3.8yrsVeri yokVeri yok

3.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: ADIL's management team is considered experienced (3.8 years average tenure).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Cary Claiborne
CEO, President & Director3yrsUS$801.62k0.95%
$ 61.4k
Kevin Schuyler
Chairman & Lead Independent Director8.6yrsUS$60.22k0.013%
$ 829.4
Tony Goodman
COO & Director7.3yrsUS$261.93k0.0055%
$ 353.3
James Newman
Independent Director10.2yrsUS$56.22k0.21%
$ 13.7k
Robertson Gilliland
Independent Director10.2yrsUS$53.22k0%
$ 0
J. Anderson
Independent Director9.8yrsUS$59.22k0%
$ 0
Giovanni Addolorato
Chairperson of Scientific Advisory Board6yrsVeri yokVeri yok
Tomáš Zima
Member of the Scientific Advisory Board5.8yrsVeri yokVeri yok
Sebastian Mueller
Member of Scientific Advisory Board5.8yrsVeri yokVeri yok

7.3yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ADIL's board of directors are considered experienced (7.3 years average tenure).